REGENXBIO Q4 Earnings Call Highlights [Yahoo! Finance]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Yahoo! Finance
FDA engagement to pursue an accelerated BLA after Phase I/II results showing a ~ mean functional improvement and no serious adverse events reported to date. MPS programs and safety : REGENXBIO received a CRL for RGX-121 and clinical holds for RGX-111/RGX-121 after an independent analysis detected an AAV vector genome integration event with clonal insertion into proto-oncogene PLAG1 linked to tumor formation; the company is preparing a CRL response and seeking a Type A meeting to address the holds. Ophthalmology catalysts and runway : The AbbVie partnership is a near-term catalyst—first dosing in the NAVIGATE DR trial is expected next quarter and would trigger a $100 million milestone, with wet AMD pivotal readouts due in Q4 2026 ; REGENXBIO reported $241 million in cash, funding operations into early 2027 (potentially into H2 2027 with milestone/royalty proceeds). Interested in REGENXBIO Inc.? Here are five stocks we like better. REGENXBIO (NASDAQ:RGNX) outlined a slate of nea
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026PR Newswire
- REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Regenxbio outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases [Seeking Alpha]Seeking Alpha
- REGENXBIO (RGNX) had its "overweight" rating reaffirmed by Morgan Stanley.MarketBeat
RGNX
Earnings
- 3/5/26 - Miss
RGNX
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/12/26 - Form 424B5
- RGNX's page on the SEC website